Form 4: Abbott Laboratories Executive Vice President Hubert L. Allen Reports Stock Transactions

Executive Vice President Hubert L. Allen of Abbott Laboratories reports the exercise of stock options and subsequent sale of shares on October 21, 2024.

Summary

• On October 21, 2024, Hubert L. Allen, an Executive Vice President at Abbott Laboratories, exercised stock options to acquire 157,421 common shares at a price of $47 per share.
• Following the exercise of these options, Allen sold a total of 157,421 shares in multiple transactions at weighted average prices of $118.81, $118.15, and $116.98.
• After these transactions, Allen directly owns 184,806 common shares of Abbott Laboratories.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions, with no inherent positive or negative sentiment. It simply reflects the executive's actions regarding their stock holdings.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, providing transparency to investors about insider activity. It's common for executives to exercise stock options and sell shares for personal financial management.

Comparison to Industry Standards

• Executive stock option exercises and sales are a common practice across publicly traded companies, including Abbott's competitors such as Johnson & Johnson, Medtronic, and Danaher.
• The timing and volume of these transactions are often influenced by factors such as personal financial planning, company performance, and market conditions.
• Similar filings can be observed for executives at comparable companies, reflecting standard compensation practices and regulatory requirements.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the overall trading volume of Abbott Laboratories.
• The transactions provide transparency to stakeholders regarding executive compensation and stock ownership.

Key Dates